{
    "2020-12-09": [
        [
            {
                "time": "",
                "original_text": "广东医疗器械抽检13%批次不合格 涉益丰药店海王星辰康泽药业子公司 产品问题",
                "features": {
                    "keywords": [
                        "医疗器械",
                        "抽检",
                        "不合格",
                        "益丰药店",
                        "海王星辰",
                        "康泽药业"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "2021年"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
                "features": {
                    "keywords": [
                        "医药",
                        "白酒",
                        "2021年度策略",
                        "次新股",
                        "圣农发展"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "白酒"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药生物",
                        "投资策略",
                        "2021年"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}